NCT02344147: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
|
|
| Active, not recruiting | 1 | 30 | US | Ixabepilone, BMS 247550, BMS-247550, Temsirolimus, CCI-779, Torisel, Pharmacological Study, pharmacological studies | Mayo Clinic, National Cancer Institute (NCI) | Adult Solid Neoplasm | 06/16 | | | |
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
|
|
| Active, not recruiting | 1 | 22 | US | Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Adult Solid Neoplasm | 06/18 | 03/25 | | |
